

## Media Release

30 October 2023

---

### PHARMAXIS QUARTERLY SHAREHOLDER UPDATE AND INVESTOR BRIEFING

---

**Tuesday 31 October 2023 at 10.00am**

Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 31 October 2023.

Investors and analysts are invited to participate in a virtual investor briefing by the Company's chief executive officer Mr Gary Phillips at 10.00am AEDT on Tuesday 31 October 2023.

The event will consist of a short presentation of the Company's progress over the past quarter and future plans followed by a Q&A session from attendees.

The event is free to attend, and investors should register in advance using the following registration link:

<https://www.pharmaxis.com.au/investor-centre/investor-briefing/>

Upon registration, instructions for joining the session will be sent via email.

To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to:  
[david.mcgarvey@pharmaxis.com.au](mailto:david.mcgarvey@pharmaxis.com.au)

#ENDS#

**SOURCE:** Pharmaxis Ltd, Sydney, Australia

**AUTHORISED FOR RELEASE TO ASX BY:**

David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203,  
E [david.mcgarvey@pharmaxis.com.au](mailto:david.mcgarvey@pharmaxis.com.au)

**CONTACT:**

**Media:** Felicity Moffatt: T +61 418 677 701, E [felicity.moffatt@pharmaxis.com.au](mailto:felicity.moffatt@pharmaxis.com.au)

**Investor Relations:** Rudi Michelson (Monsoon Communications) T +61 411 402 737,  
E [rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

Join the Pharmaxis mailing list [here](#)

## **About Pharmaxis**

Pharmaxis Ltd is an Australian clinical stage drug development company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing royalties.

Pharmaxis is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that began recruitment in Q1 2021 and reported final interim data in July 2023.

Other drug candidates being developed from Pharmaxis' amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and other inflammatory diseases. PXS-4728 is being studied in collaboration with Parkinson's UK as a best in class SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. [www.pharmaxis.com.au](http://www.pharmaxis.com.au)

At the 2023 annual general meeting to be held on 28 November 2023, Pharmaxis shareholders will be asked to approve a change in the name of the company to Syntara Limited (ASX: SNT).

## **Forward-Looking Statements**

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.